Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University’s Medical Sciences Business Development & Partnering team reflect on 2018 and look forward to 2019

2018 was a landmark year for the Divisional Business Development and Partnering Team. In addition to strengthening our research alliances with UCB, Novo Nordisk, Celgene, Pfizer and Bayer, we also saw some important strategic developments. We were delighted to welcome Novo Nordisk to Oxford in the summer, with the opening of the Novo Nordisk Oxford Research Centre based on the Old Road Campus which will strengthen our research partnership. The summer also saw the opening of the BioEscalator, a hub for new and developing life science innovations.

We were thrilled to learn that Innovate UK and industry are to invest more than £17.5 million in the University of Oxford to develop artificial intelligence (AI) healthcare applications. Funding will be provided through the Government’s Industrial Strategy Challenge Fund by as part of a £50 million investment to establish a network of digital pathology, imaging and AI centres, to drive innovation in the use of AI for improved diagnosis and delivery of precision treatments.

We have continued to deliver a range of events to engage our research community with industry, including the 2018 AIMday in Biomedical Imaging which was a huge success and we hope to repeat this in 2019 with a new AIMday in Advanced Therapies and Regenerative Medicine.

More recently, the Oxford MIT Healthcare Technologies of the Future Conference saw the University of Oxford and MIT come together to strengthen and share our industry networks and highlight some of our spin outs.

We are delighted to have developed, delivered and supported so many alliances, collaborations, opportunities and events in 2018 and look forward to a successful and fruitful 2019.

Find out more about the Business Development Team

Similar stories

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.